The Zhitong Finance App learned that DBS released a research report saying that Longfeng Group (02290.HK) is the largest pharmaceutical retailer in Hong Kong in terms of retail sales, with a market share of 5.2% in fiscal year 2025, ranking third in pharmaceuticals, health and beauty, with a market share of 5.8%. For the first time, it covered a “buy” rating, with a target price of HK$7.98.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.